PRTA
Prothena Corporation
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Novo Nordisk received FDA Fast Track designation for Coramitug in ATTR amyloidosis with cardiomyopathyApr 28, 2026
- Prothena's partner Bristol Myers Squibb obtains FDA Fast Track designation for anti-MTBR-Tau antibody BMS-986446 to treat Alzheimer'sOct 2, 2025
- Prothena provides update on PRX012 and announces results from Phase 1 ASCENT clinical programAug 29, 2025
- Prothena announces that Novo Nordisk will advance Coramitug (formerly PRX004) into Phase 3 development for ATTR amyloidosis with cardiomyopathyAug 7, 2025
- Prothena's partner Roche to advance Prasinezumab into Phase III for early Parkinson’sJun 16, 2025